Bio-Techne Corporation TECH recently announced new advancements in its spatial biology portfolio for the RNAscope ISH ...
New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL ...
The News-Times on MSN
Builder’s plan to add 12 homes to gated community near Danbury High School gets environmental review
The proposed area of development consists of a relatively flat, partially cleared ridgetop with steeper, wooded side slopes ...
CD19-targeting UB-VV11 became the first in vivo CAR-T cell therapy to be cleared for human testing by the FDA last year, and ...
First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ARV-102, a PROTAC LRRK2 Degrader, in Healthy Participants Date & Time : Oct.
The FDA has granted fast track designation to UB-VV111 for the treatment of relapsed/refractory large B-cell lymphoma (LBCL) following 2 or more prior lines of therapy and relapsed/refractory chronic ...
Genmab acquires Merus for $8bn, adding promising oncology asset petosemtamab. Check out my thoughts on this deal and my ...
Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the ...
Post-CAR T infection prophylaxis should follow European Hematology Association/European Society for Blood and Marrow ...
COUR Pharma, a clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies for autoimmune diseases, announced today the U.S. Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback